Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 3, 2004, Pages 183-197

  Fontana, Robert J ^a,f   Everson, Gregory T ^b   Tuteja, Sony ^c   Vargas, Hugo E ^d   Shiffman, Mitchell L ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Cincinnati Transplant Institute   (United States)

^d MAYO CLINIC   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

AFP; CHC; Child Turcotte Pugh; Chronic hepatitis C; CTP; ECM; Extracellular matrix; HAI; HCC; HCV; Hepatitis C virus; Hepatocellular carcinoma; Histological activity index; QLFTs; Quantitative liver function tests; SVR; fetoprotein

Indexed keywords

ALCOHOL; ALPHA2A INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABDOMINAL WALL HERNIA; ASSOCIATION; BACTERIAL ARTHRITIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DEMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMPYEMA; ENVIRONMENTAL FACTOR; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY OF MEDICINE; HOST; HUMAN; HYPERBILIRUBINEMIA; HYPOTHYROIDISM; IMMUNOLOGY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; NEUTROPENIA; NUTRITION; PANCREATITIS; PATIENT CARE; REVIEW; SIDE EFFECT; STANDARDIZATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 1442348322     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00002-3     Document Type: Article

References (127)

1. Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.S. The past incidence of hepatitis C virus infection implications for the future burden of chronic liver disease in the United States. Hepatology. 31:2000;777-782.
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., Margolis H.S., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 341:1999;556-562.
3. Kim W.R. The burden of hepatitis C in the United States. Hepatology. 36:2002;S30-S34.
4. Hoofnagle J.H. Hepatitis C the clinical spectrum of disease. Hepatology. 26:(suppl 1):1997;15S-20S.
5. Seeff L.B., Miller R.N., Rabkin C.S., Buskell-Bales Z., Straley-Eason K.D., Smoak B.L., Johnson L.D., Lee S.R., Kaplan E.L., et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 132:2000;105-111.
6. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant. 1:2001;197-203.
7. Davis G.L., Albright J.E., Cook S.F., Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 9:2003;331-338.
8. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., Furuta S., Akahane Y., Nishioka K., Purcell R.H., Alter H.J. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma analysis by detection of antibody to hepatitis C virus. Hepatology. 12:1990;671-675.
9. Tong M.J., el-Farra N.S., Reikes A.R., Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
10. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inoue O., Hashimoto E., Lefkowitch J.H., Ludwig J., Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
11. Niederau C., Lange S., Heintges T., Erhardt A., Buschkamp M., Hurter D., Nawrocki M., Kruska L., Hensel F., Wolfgang P., Haussinger D. Prognosis of chronic hepatitis C results of a large, prospective cohort study. Hepatology. 28:1998;1687-1695.
12. Gordon S.C., Elloway R.S., Long J.C., Dmuchowski C.F. The pathology of hepatitis C as a function of mode of transmission blood transfusion vs intravenous drug use. Hepatology. 18:1993;1338-1343.
13. Di Bisceglie A.M., Goodman Z.D., Ishak K.G., Hoofnagle J.H., Melpolder J.J., Alter H.J. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 14:1991;969-974.
14. Kenny-Walsh E., the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 340:1999;1228-1233.
15. Wiese M., Berr F., Lafrenz M., Porst H., Olsen V. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany a 20 year multicenter study. Hepatology. 32:2000;91-96.
16. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology. 45:1998;1206-1213.
17. Alberti A., Chemello L., Benvegnu L. Natural history of hepatitis C. J Hepatol. 31:(suppl 1):1999;17-24.
18. Roffi L., Ricci A., Ogliari C., Scalori A., Minola E., Colloredo G., Donada C., Ceriani R., Rinaldi G., Paris B., Fornaciari G., Morales R., Del Poggio P., Sangiovanni A., Buonocore M., Bellia V., Riboli P., Nava M.C., Panizzuti F., Piperno A., Pozzi M., Pioltrelli P., Mancia G., et al. HCV genotypes in Northern Italy a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol. 29:1998;701-706.
19. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 34:2001;730-739.
20. Lau J.Y., Davis G.L., Kniffen J., Qian K.P., Urdea M.S., Chan C.S., Mizokami M., Neuwald P.D., Wilber J.C., et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
21. Fanning L., Kenny E., Sheehan M., Cannon B., Whelton M., O'Connell J., Collins J.K., Shanahan F. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology. 29:1999;904-907.
22. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 288:2000;339-344.
23. Minola E., Prati D., Suter F., Maggiolo F., Caprioli F., Sonzogni A., Fraquelli M., Paggi S., Conte D., et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 99:2002;4588-4591.
24. Bataller R., North K.E., Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis a critical appraisal. Hepatology. 37:2003;493-503.
25. Pradat P., Alberti A., Poynard T., Esteban J.I., Weiland O., Marcellin P., Badalamenti S., Trepo C. Predictive value of ALT levels for histologic findings in chronic hepatitis C a European collaborative study. Hepatology. 36:2002;973-977.
26. Persico M., Persico E., Suozzo R., Conte S., De Seta M., Coppola L., Palmentieri B., Sasso F.C., Torella R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 118:2000;760-764.
27. Ghany M.G., Kleiner D.E., Alter H., Doo E., Khokar F., Promrat K., Herion D., Park Y., Liang T.J., Hoofnagle J.H. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 124:2003;97-104.
28. Kronenberger B., Ruster B., Lee J.H., Sarrazin C., Roth W.K., Herrmann G., Zeuzem S. Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. J Hepatol. 33:2000;640-647.
29. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 349:1997;825-832.
30. Vogt M., Lang T., Frosner G., Klingler C., Sendl A.F., Zeller A., Wiebecke B., Langer B., Meisner M.D., Hess M.D. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 341:1999;866-870.
31. Thomas D.L. Hepatitis C and human immunodeficiency virus infection. Hepatology. 36:2002;S201-S209.
32. Seeff L.B., Buskell-Bales Z., Wright E.C., Durako S.J., Alter H.J., Iber F.L., Hollinger F.B., Gitnick G., Knodell R.G., Perrillo R.P. Long-term mortality after transfusion-associated non-A, non-B hepatitis the National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 327:1992;1906-1911.
33. Seeff L.B., Hollinger F.B., Alter H.J., Wright E.C., Cain C.M., Buskell Z.J., Ishak K.G., Iber F.L., Samanta A., Koreta R., Perrillo R.P. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis a National Heart, Lung, and Blood Institute collaborative study. Hepatology. 33:2001;455-463.
34. Dienstag J.L. The role of liver biopsy in chronic hepatitis C. Hepatology. 36:2002;S152-S160.
35. Saadeh S., Cammell G., Carey W.D., Younossi Z., Barnes D., Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 33:2001;196-200.
36. Fontana R.J., Lok A.S. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 36:2002;S57-S64.
37. Friedman S.L. Evaluation of fibrosis and hepatitis C. Am J Med. 107:1999;27S-30S.
38. Sobesky R., Mathurin P., Charlotte F., Moussalli J., Olivi M., Vidaud M., Ratziu V., Opolon P., Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C a dynamic view - the Multivirc Group. Gastroenterology. 116:1999;378-386.
39. Poniachik J., Bernstein D.E., Reddy K.R., Jeffers L.J., Coelho-Little M.E., Civantos F., Schiff E.R., et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 43:1996;568-571.
40. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., Kuroki T., Nishiguchi S., Sata M., Yamada G., Fujiyama S., Yoshida H., Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 132:2000;517-524.
41. Kage M., Shimamatu K., Nakashima E., Kojiro M., Inoue O., Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C morphometric analysis of repeated biopsies. Hepatology. 25:1997;1028-1031.
42. Guido M., Rugge M., Chemello L., Leandro G., Fattovich G., Giustina G., Cassaro M., Alberti A. Liver stellate cells in chronic viral hepatitis the effect of interferon therapy. J Hepatol. 24:1996;301-307.
43. Westin J., Lagging L.M., Wejstal R., Norkrans G., Dhillon A.P. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver. 19:1999;183-187.
44. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., Feng Z., Reddy K.R., Schiff E.R., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 97:2002;2614-2618.
45. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 20:1994;15-20.
46. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., DePamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 343:2000;1673-1680.
47. Shiffman M.L., Hofmann C.M., Contos M.J., Luketic V.A., Sanyal A.J., Sterling R.K., Ferreira'-Gonzalez A., Mills A.S., Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 117:1999;1164-1172.
48. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C International Hepatitis Interventional Therapy Group. N Engl J Med. 339:1998;1493-1499.
49. Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis the Knodell histology activity index and beyond. Hepatology. 31:2000;241-246.
50. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., MacSween R.N.M., Phillips M.J., Portmann B.G., Poulsen H., Scheuer P.J., Schmid M., Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol. 22:1995;696-699.
51. Duchatelle V., Marcellin P., Giostra E., Bregeaud L., Pouteau M., Boyer N., Auperin A., Guerret S., Erlinger S., Henin D., Degott C. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C quantitative assessment by a morphometric method. J Hepatol. 29:1998;20-28.
52. Herold C., Heinz R., Niedobitek G., Schneider T., Hahn E.G., Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver. 21:2001;260-265.
53. Poynard T., Imbert-Bismut F., Ratziu V., Chevret S., Jardel C., Moussalli J., et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus longitudinal validation in a randomized trial. J Viral Hepatol. 9:2002;128-133.
54. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection a prospective study. Lancet. 357:2001;1069-1075.
55. Johansen J.S., Christoffersen P., Moller S., Price P.A., Henriksen J.H., Garbarsch C., Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 32:2000;911-920.
56. McHutchison J.G., Blatt L.M., de Medina M., Craig J.R., Conrad A., Schiff E.R., Tong M.J. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology Consensus Interferon Study Group. J Gastroenterol Hepatol. 15:2000;945-951.
57. Guechot J., Laudat A., Loria A., Serfaty L., Poupon R., Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem. 42:1996;558-563.
58. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P., Nevens F., Solinas A., Mura D., Brouwer J.T., Thomas H., Njapoum C., Casarin C., Bonetti P., Fuschi P., Basho J., Tocco A., Bhalla A., Galassini R., Noventa F., Schalm S.W., Realdi G. Morbidity and mortality in compensated cirrhosis type C a retrospective follow-up study of 384 patients. Gastroenterology. 112:1997;463-472.
59. Hu K.Q., Tong M.J. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 29:1999;1311-1316.
60. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M.H., Albrecht J.K., International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet. 358:2001;958-965.
61. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. Jr, Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982.
62. Hadziyannis S., Cheinquer H., Morgan T., Diago M., Jenson D., Sette H.J. Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV) efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining the effect of duration of treatment and RBV dose. (abstract 536) The European Association for the Study of the Liver. 2002.
63. Helbling B., Stamenic I., Cerny A., Borovicka J., Gonvers J., Muellhaupt B., Renner E.L., et al. Pegylated (40kDa, branched) interferon alfa-2a (PEG-IFN) and ribavirin (RIBA) in IFN-naive patients with hepatitis C and advanced fibrosis/cirrhosis interim results of a randomized, controlled study. (abstr 84) Gastronenterology. 122:2002;A627.
64. Peck-Radosavljevic M., Wichlas M., Homoncik-Kraml M., Kreil A., Hofer H., Jessner W., Gangl A., Ferenci P. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology. 123:2002;141-151.
65. Ghalib R., Levine C., Hassan M., McClelland T., Goss J., Stribling R., Seu P., Patt Y.Z. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology. 37:2003;1165-1171.
66. Everson G. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low-accelerating- dose regimen). (abstr 536) Hepatology. 36:2002;297A.
67. Crippin J.S., McCashland T., Terrault N., Sheiner P., Charlton M.R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 8:2002;350-355.
68. Shiffman M.L., Hofmann C.M., Thompson E.B., Ferreira-Gonzalez A., Contos M.J., Koshy A., Luketic V.A., Sanyal A.J., Mills A.S., Garrett C.T. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatology. 26:1997;780-785.
69. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., Ling M.H., Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 122:2002;1303-1313.
70. Lau D.T., Kleiner D.E., Ghany M.G., Park Y., Schmid P., Hoofnagle J.H. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 28:1998;1121-1127.
71. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Nishiguchi S., Kuroki T., Imazeki F., Yikosuka O., Kindyama S., Yamada G., Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan: IHIT Study Group - Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 131:1999;174-181.
72. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 36:2002;S74-S83.
73. Alric L., Duffaut M., Selves J., Sandre K., Mularczyck M., Izopet J., Desmorat H., Bureau C., Chauche N., Dalbergue B., Vinel J.P. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response results of a randomized trial. J Hepatol. 35:2001;272-278.
74. Shiffman M. Retreatment of HCV non-responders with peginterferon and ribavirin results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. (abstr) Hepatology. 36:2002;295A.
75. Gross J.B., Kwo P., Afdhal N., et al. Interim results in the RENW trial a dose comparison study of high-dose peginterferon alfa-2b and ribavirin for interferon/ribavirin non-responders with chronic hepatitis C. (abstr) Hepatology. 36:2002;783A.
76. Lawitz E.J., Bala N.S., Becker S., Brown G., Davis M., Dhar R., Ganeshappa K.P., Gordon S., Holtzmuller K., Jeffries M., Li J., Monsour H., Nader P., Rosenfield T., Tolman K., Kadakia S. Pegylated interferon alfa-2b and ribavirin for hepatitis C patients who were non-responders to previous therapy. Gastroenterology. 124:(Suppl 1):2003;T1239A.
77. Afdhal N., Levine R., Black M. Colchicine versus PEG-Intron long-term 1 year data from the COPILOT study. (abstr) Gastroenterology. 122:2002;P-218.
78. National Institutes of Health Consensus Development Conference Panel statement. management of hepatitis C. Hepatology. 26:1997;2S-10S.
79. Prevention of hepatitis A through active or passive immunization. recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 45:1996;1-30.
80. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G., Ferraro T., Concia E. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 338:1998;286-290.
81. Keeffe E.B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 90:1995;201-205.
82. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 75:1998;347-354.
83. Keeffe E.B., Iwarson S., McMahon B.J., Lindsay K.L., Koff R.S., Manns M., Baumgarten R., Wiese M., Fourneau M., Safary A., Clemens R., Krause D.S. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 27:1998;881-886.
84. Grace N.D. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol. 92:1997;1081-1091.
85. D'Amico G., Pagliaro L., Bosch J. Pharmacological treatment of portal hypertension an evidence-based approach. Semin Liver Dis. 19:1999;475-505.
86. Sallie R., Di Bisceglie A.M. Viral hepatitis and hepatocellular carcinoma. Gastroenterol Clin North Am. 23:1994;567-579.
87. Hasan F., Jeffers L.J., De Medina M., Reddy K.R., Parker T., Schiff E.R., Houghton M., Choo Q.L., Kuo G. Hepatitis C-associated hepatocellular carcinoma. Hepatology. 12:1990;589-591.
88. Yu M.C., Tong M.J., Coursaget P., Ross R.K., Govindarajan S., Henderson B.E. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst. 82:1990;1038-1041.
89. El-Serag H.B., Richardson P.A., Everhart J.E. The role of diabetes in hepatocellular carcinoma a case-control study among United States Veterans. Am J Gastroenterol. 96:2001;2462-2467.
90. Deuffic S., Poynard T., Buffat L., Valleron A.J. Trends in primary liver cancer. Lancet. 351:1998;214-215.
91. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan projection to other countries in the foreseeable future. Oncology. 62:(suppl 1):2002;8-17.
92. Degos F., Christidis C., Ganne-Carrie N., Farmachidi J.P., Degott C., Guettier C., Trinchet J.-C., Beaugrand M., Chevret S. Hepatitis C virus related cirrhosis time to occurrence of hepatocellular carcinoma and death. Gut. 47:2000;131-136.
93. Castells L., Vargas V., Gonzalez A., Esteban J., Esteban R., Guardia J. Long interval between HCV infection and development of hepatocellular carcinoma. Liver. 15:1995;159-163.
94. Solmi L., Primerano A.M., Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma results of a prospective study on 360 cases. Am J Gastroenterol. 91:1996;1189-1194.
95. Gebo K.A., Chander G., Jenckes M.W., Ghanem K.G., Herlong H.F., Torbenson M.S., El-Kamary S.S., Bass E.B. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C a systematic review. Hepatology. 36:2002;S84-S92.
96. Nguyen M.H., Garcia R.T., Simpson P.W., Wright T.L., Keeffe E.B. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 36:2002;410-417.
97. Velazquez R.F., Rodriguez M., Navascues C.A., Linares A., Perez R., Sotorrios N.G., Martinez I., Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 37:2003;520-527.
98. Donato F., Tagger A., Gelatti U., Parrinello G., Boffetta P., Albertini A., Decarli A., Trevisi P., Ribero L., Martelli C., Porru S., Nardi G. Alcohol and hepatocellular carcinoma the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 155:2002;323-331.
99. Harris D.R., Gonin R., Alter H.J., Wright E.C., Buskell Z.J., Hollinger F.B., et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med. 134:2001;120-124.
100. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., Nolt K., Nelson K.E., Strathdee S.A., Johnson L., Lacyendecker O., Boitnott J., Wilson L.E., Vlahov D. The natural history of hepatitis C virus infection host, viral, and environmental factors. JAMA. 284:2000;450-456.
101. Kim W.R., Gross J.B. Jr, Poterucha J.J., Locke G.R. 3rd, Dickson E.R. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology. 33:2001;201-206.
102. Khan K.N., Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol Alcohol. 35:2000;286-295.
103. Ohnishi K., Matsuo S., Matsutani K., Itahashi M., Kakihara K., Suzuki K., Ito S., Fujiwara K. Interferon therapy for chronic hepatitis C in habitual drinkers comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 91:1996;1374-1379.
104. Tabone M., Sidoli L., Laudi C., Pellegrino S., Rocca G., Della Monica P., Fracchia M., Galatol G., Molinaro G.C., Arico S., Pera A. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepatol. 9:2002;288-294.
105. Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., Bacon B.R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 102:1992;2108-2113.
106. Riggio O., Montagnese F., Fiore P., Folino S., Giambartolomei S., Gandin C., Caroll S., Violante N., Quinti I., Merli M., Senofonte O., Capocaccia L. Iron overload in patients with chronic viral hepatitis how common is it? Am J Gastroenterol. 92:1997;1298-1301.
107. Piperno A., D'Alba R., Fargion S., Roffi L., Sampietro M., Parma S., Arosio V., Fare M., Fiorelli G. Liver iron concentration in chronic viral hepatitis a study of 98 patients. Eur J Gastroenterol Hepatol. 7:1995;1203-1208.
108. Bacon B.R., Britton R.S. The pathology of hepatic iron overload a free radical-mediated process? Hepatology. 11:1990;127-137.
109. Giannini E., Mastracci L., Botta F., Romagnoli P., Fasoli A., Risso D., Faravelli T., Ceppa P., Lantieri P.B., Icardi G.C., Testa R. Liver iron accumulation in chronic hepatitis C patients without HFE mutations relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. Eur J Gastroenterol Hepatol. 13:2001;1355-1361.
110. Thorburn D., Curry G., Spooner R., Spence E., Oien K., Halls D., Mills P.R., Fox R., McCruden E.A.B., MacSween R.N.M. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut. 50:2002;248-252.
111. Casaril M., Stanzial A.M., Tognella P., Pantalena M., Capra F., Colombari R., Corrocher R., et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology. 47:2000;220-225.
112. Hezode C., Cazeneuve C., Coue O., Roudot-Thoraval F., Lonjon I., Bastie A., Duvoux C., Pawlotsky J.M., Zafrani E.S., Amselem S., Dhumeaux D. Liver iron accumulation in patients with chronic active hepatitis C prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol. 31:1999;979-984.
113. Chapoutot C., Esslimani M., Joomaye Z., Ramos J., Perney P., Laurent C., Fabbro-Peray P., Carrey D., Domerque J., Blanc F. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut. 46:2000;711-714.
114. Olynyk J.K., Reddy K.R., Di Bisceglie A.M., Jeffers L.J., Parker T.I., Radick J.L., Schiff E.R., Bacon B.R. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology. 108:1995;1104-1109.
115. Distante S., Bjoro K., Hellum K.B., Myrvang B., Berg J.P., Skaug K., Raknerud N., Bell H. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver. 22:2002;269-275.
116. Fontana R.J., Israel J., LeClair P., Banner B.F., Tortorelli K., Grace N., Levine R.A., Fiarman G., Thim Michael, Tavill A.S., Bonkovsky H.L. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 31:2000;730-736.
117. Hourigan L.F., Macdonald G.A., Purdie D., Whitehall V.H., Shorthouse C., Clouston A., Powell E. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 29:1999;1215-1219.
118. Monto A., Alonzo J., Watson J.J., Grunfeld C., Wright T.L. Steatosis in chronic hepatitis C relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 36:2002;729-736.
119. Ortiz V., Berenguer M., Rayon J.M., Carrasco D., Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 97:2002;2408-2414.
120. Hickman I.J., Clouston A.D., Macdonald G.A., Purdie D.M., Prins J.B., Ash S., Jonsson J.R., Powell E.E. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 51:2002;89-94.
121. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 122:2002;889-896.
122. Everson G.T. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl. 8:2002;S19-S27.
123. Dieterich D., Pockros P., Schiff E., Shiffman M., Sulkowski M.S., Wright T.L. Epoetin alfa (Procrit) once weekly maintains ribavirin dose in hepatitis C virus (HCV)-infected patients treated with combination therapy interim results of a randomized, double-blind, placebo-controlled study. (abstr) Hepatology. 36:2002;286A.
124. Rustgi V., Lee P., Finnegan S., Ershler W. Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon/ribavirin therapy in hepatitis C patients with thrombocytopenia. (abstr) Hepatology. 36:2002;361A.
125. Hinrichsen H., Benhamou J.P., Reiser M., Sentjens R., Calleja J.L., Cronlein J., Steinmann G., et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor in patients with chronic hepatitis C genotype 1. (abstr) Hepatology. 36:2002;866A.
126. Di Bisceglie A.M., McHutchison J., Rice C.M. New therapeutic strategies for hepatitis C. Hepatology. 35:2002;224-231.
127. Safadi R., Friedman S.L. Hepatic fibrosis role of hepatic stellate cell activation. Med Gen Med. 4:2002;27.